| Oct 30 |
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
|
| Oct 29 |
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
|
| Oct 21 |
uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring
|
| Oct 15 |
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
|
| Oct 15 |
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
|
| Oct 9 |
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
|
| Sep 23 |
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
|
| Sep 13 |
uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago
|
| Aug 15 |
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
|
| Aug 6 |
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
|
